MedTrace Logo

A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant

NCT02057484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2300

Last updated 2024-10-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the impact of Advagraf, prolonged-release, once daily tacrolimus formulation, on long-term graft survival in kidney and liver allograft recipients. This study will also evaluate the overall long-term impact of Advagraf on kidney and liver allograft recipients.

Conditions

  • Liver Transplant
  • Kidney Transplant

Interventions

DRUG

Tacrolimus

oral

Sponsors & Collaborators

  • Astellas Pharma Europe Ltd.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Europe Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-03
Primary Completion
2017-10-17
Completion
2017-10-17

Countries

  • Austria
  • Belarus
  • Belgium
  • Canada
  • Czechia
  • Estonia
  • Finland
  • France
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Russia
  • Slovakia
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02057484 on ClinicalTrials.gov